About eyepoint pharmaceuticals - EYPT
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
EYPT At a Glance
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown, Massachusetts 02472
| Phone | 1-617-926-5000 | Revenue | 43.27M | |
| Industry | Pharmaceuticals: Major | Net Income | -130,870,000.00 | |
| Sector | Health Technology | Employees | 165 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
EYPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.692 |
| Price to Book Ratio | 1.511 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.496 |
| Enterprise Value to Sales | 1.655 |
| Total Debt to Enterprise Value | 0.323 |
EYPT Efficiency
| Revenue/Employee | 262,260.606 |
| Income Per Employee | -793,151.515 |
| Receivables Turnover | 71.29 |
| Total Asset Turnover | 0.112 |
EYPT Liquidity
| Current Ratio | 7.815 |
| Quick Ratio | 7.768 |
| Cash Ratio | 7.562 |
EYPT Profitability
| Gross Margin | 91.422 |
| Operating Margin | -337.055 |
| Pretax Margin | -302.221 |
| Net Margin | -302.429 |
| Return on Assets | -33.832 |
| Return on Equity | -43.419 |
| Return on Total Capital | -36.393 |
| Return on Invested Capital | -41.573 |
EYPT Capital Structure
| Total Debt to Total Equity | 6.866 |
| Total Debt to Total Capital | 6.425 |
| Total Debt to Total Assets | 5.521 |
| Long-Term Debt to Equity | 6.496 |
| Long-Term Debt to Total Capital | 6.078 |